Christian Waage, EVP of Tech Ops and Admin, has demonstrated a consistent pattern of acquiring shares in two companies—Gossamer Bio (GOSS) and Heron Therapeutics (HRTX)—without any recorded sales, according to SEC Form 4 filings. His 26 reported transactions, all classified as acquisitions, total $62,107 in value, with the bulk stemming from a January 30, 2025, purchase of HRTX shares worth $62,107. The remaining transactions, primarily involving GOSS, show no disclosed dollar value, suggesting they may represent awards or other non-cash acquisitions. Waage’s most recent activity includes multiple GOSS transactions on March 19, 2026, all coded as derivative holdings (A) or dispositions (D), though again with no associated monetary value.
Notably, Waage’s trading history reveals a long-term accumulation strategy, with no sales across either holding. His earliest recorded transaction dates back to January 19, 2024, involving HRTX, followed by additional HRTX acquisitions in early 2025 and GOSS transactions spanning late 2025 through early 2026. The absence of sell-side activity, combined with repeated acquisitions—particularly in GOSS—suggests a sustained commitment to these positions. However, the lack of recent high-value purchases since the 2025 HRTX buy leaves open whether his accumulation phase has slowed or shifted toward non-monetary equity awards.
AI-assisted summary